129 related articles for article (PubMed ID: 26287338)
1. [Glucocorticoid combined with ulinastatin in treatment of Kawasaki disease in children: a non-randomized controlled clinical trial].
Zhao DM; Yin QL; Ji XH; Haiweier M; Meng GY; Cheng QT; Ju LJ
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):780-5. PubMed ID: 26287338
[TBL] [Abstract][Full Text] [Related]
2. Ulinastatin therapy in kawasaki disease.
Iwashima S; Seguchi M; Matubayashi T; Ohzeki T
Clin Drug Investig; 2007; 27(10):691-6. PubMed ID: 17803344
[TBL] [Abstract][Full Text] [Related]
3. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for coronary artery lesions in children with Kawasaki disease.
Duan J; Jiang H; Lu M
Arch Argent Pediatr; 2020 Oct; 118(5):327-331. PubMed ID: 32924395
[TBL] [Abstract][Full Text] [Related]
8. [Changes of P-selectin and E-selectin in children with Kawasaki disease].
Qiu Y; Wu J; Fang XY; Lin Z; Wu BY; Cai RY; Xu XY; Zheng H
Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):688-92. PubMed ID: 15482673
[TBL] [Abstract][Full Text] [Related]
9. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
12. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
14. [Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease].
Saji T
Nihon Rinsho; 2008 Feb; 66(2):343-8. PubMed ID: 18265458
[TBL] [Abstract][Full Text] [Related]
15. Relationship between ocular manifestations, laboratory findings, echocardiographic findings, and intravenous immunoglobulin resistance in Kawasaki disease.
Jari M; Esmaeili H
Pediatr Rheumatol Online J; 2024 May; 22(1):50. PubMed ID: 38693550
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
[TBL] [Abstract][Full Text] [Related]
17. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
Wang QQ; Zheng LY; Zhao S
Turk J Pediatr; 2023; 65(4):640-649. PubMed ID: 37661679
[TBL] [Abstract][Full Text] [Related]
18. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
19. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
20. Do cytokines correlate with refractory Kawasaki disease in children?
Wang Y; Qian SY; Yuan Y; Wang Q; Gao L; Chen X; Yu X; Zhen Z
Clin Chim Acta; 2020 Jul; 506():222-227. PubMed ID: 32156603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
